View Author
patient myeloma response treatment bortezomib therapy study bene fit survival trial blood cancer signi ficantly disease month cycle lenalidomide dexamethasone regimen signi celgene cohort days 1-4 comorbidity thalidomide quality ն 75 years transplantation group result j clin oncol outcome journal melphalan phase prednisone effect richardson ficantly erasmus mc disability ef ficacy prognostic vulnerability apex trial honoraria condition palumbo janssen-cilag oncol high-dose agent criteria progression frailty analysis 1-4 adult british journal novel agents combination mortality index blade number 100 mg /d novel 6- wk cycles johnson department cell transplantation ficacy hematology increase table grade university incidence status uniform response criteria
2 Most Recent Publications
|
Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)
(Article)
Palumbo, A. Bringhen, S. Zweegman, S. Terpos, E. Davies, F. Driessen, C. Gimsing, P. Gramatzki, M. Hajek, R. Johnsen, H.E. Da Costa, F.L. Sezer, O. Ludwig, H. Spencer, A. Beksaç, M. Morgan, G. Einsele, H. San Miguel, J. Sonneveld, P. Dimopoulos, M.A. Bladé, J. Mateos, M.V. Rosiñol, L. Boccadoro, M. Cavo, M. Lokhorst, H.M. |
2011-10-27
|
|
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
(Article)
Niesvizky, R. Richardson, P.G. Harousseau, J-L. Boral, A.L. Esseltine, D-L. Anderson, K.C. Bladé, J. Rajkumar, S.V. Coleman, M. Rosiñol, L. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. |
2008-10-01
|
